"Designing Growth Strategies is in our DNA"
Uveal melanoma, also referred to as intraocular melanoma is an ocular disease in which malignant cells develop in the inner tissues of the eye. According to the National Cancer Institute, uveal melanoma is a rare form of cancer but still is one of the most prevalent eye cancers in adults. Malignant tissues develop in the cells that make up melanin in the iris choroid and ciliary body. The symptoms include dark spots on the iris and blurred vision. The estimates provided by the National Cancer Institute states that there are an estimated 5.1 cases of uveal melanoma per million per year, globally.
There is no definitive Food and Drug Administration (FDA) approved standard of care for the treatment of uveal melanoma in the current scenario. Depending upon the stage of the melanoma, the treatment options include radiation therapy, plaque brachytherapy, enucleation (surgical removal of the eye) and use of chemotherapeutic agents like dacarbazine.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for uveal melanoma. For instance; Crizotinib, which is being studied by Pfizer Inc., is in Phase-2 clinical trial for testing the efficacy of Crizotinib in patients with uveal melanoma.
To know how our report can help streamline your business, Speak to Analyst
In 2018, an estimated 64.0% of the pipeline candidates for uveal melanoma were in Phase 2 stage. Most of the studies are being conducted by research institutes and pharmaceutical companies.
The report on ‘Uveal Melanoma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Uveal Melanoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Uveal Melanoma.
The report on ‘Uveal Melanoma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.